Tadalafil (BPH) — Discount Pricing

Other medications in Urology

• Tamsulosin
• Terazosin
• Tolterodine
• Vardenafil
• Vibegron
• Alfuzosin
• Avanafil
• Bethanechol

What Tadalafil (BPH) is approved for (FDA label)

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) (1.1) the signs and symptoms of benign prostatic hyperplasia (BPH) (1.2) ED and the signs and symptoms of BPH (ED/BPH) (1.3) If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks (1.4). 1.1 Erectile Dysfunction Tadalafil tablets are indicated for the treatment of erectile dysfunction (ED). 1.2 Benign Prostatic Hyperplasia Tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). 1.3 Erectile Dysfunction and Benign Prostatic Hyperplasia Tadalafil tablets are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH). 1.4 Limitation of Use If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see Clinical Studies (14.3)] .

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tadalafil (BPH) (FDA label)

2.5 mg tablets: Yellow colored, round shaped, biconvex, film-coated tablets, debossed with “2½” on one side and plain on other side. 5 mg tablets: Yellow colored, oval shaped, biconvex, film-coated tablets, debossed with “5” on one side and “S” on other side. 10 mg tablets: Yellow colored, oval shaped, biconvex, film-coated tablets, debossed with “10” on one side and “S” on other side. 20 mg tablets: Yellow colored, oval shaped, biconvex, film-coated tablets, debossed with “20” on one side and “S” on other side. Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg (3).

Source: FDA prescribing information (DailyMed). Set ID: 81222924-29d9-4031-954d-132923867b8e. SPL document ID: d1b827f1-2de5-4a6c-a8eb-534ef1b39f2b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tadalafil (BPH) (FDA label)

Most common adverse reactions (≥2%) include headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, and pain in limb (6.1). To report SUSPECTED ADVERSE REACTIONS, contact NorthStar RxLLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Tadalafil was administered to over 9,000 men during clinical trials worldwide. In trials of tadalafil for once daily use, a total of 1,434, 905, and 115 were treated for at least 6 months, 1 year, and 2 years, respectively.

Source: FDA prescribing information (DailyMed). Set ID: 81222924-29d9-4031-954d-132923867b8e. SPL document ID: d1b827f1-2de5-4a6c-a8eb-534ef1b39f2b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tadalafil (BPH) (FDA label)

Administration of tadalafil to patients using any form of organic nitrate is contraindicated. Tadalafil was shown to potentiate the hypotensive effect of nitrates (4.1). History of known serious hypersensitivity reaction to tadalafil or ADCIRCA ®* (4.2). Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3). 4.1 Nitrates Administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. In clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates [ see Clinical Pharmacology (12.2) ]. 4.2 Hypersensitivity Reactions Tadalafil is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA ®* ). Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis [see Adverse Reactions (6.2)] . 4.3 Concomitant Guanylate Cyclase (GC) Stimulators Do not use tadalafil in patients who are using a GC stimulator, such as riociguat.

Source: FDA prescribing information (DailyMed). Set ID: 81222924-29d9-4031-954d-132923867b8e. SPL document ID: d1b827f1-2de5-4a6c-a8eb-534ef1b39f2b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tadalafil (BPH) (FDA label)

Evaluation of erectile dysfunction and BPH should include an appropriate medical assessment to identify potential underlying causes, as well as treatment options. Before prescribing tadalafil, it is important to note the following: Patients should not use tadalafil if sex is inadvisable due to cardiovascular status (5.1). Use of tadalafil with alpha-blockers, antihypertensives or substantial amounts of alcohol (≥5 units) may lead to hypotension (5.6, 5.9). Tadalafil is not recommended in combination with alpha-blockers for the treatment of BPH because efficacy of the combination has not been adequately studied and because of the risk of blood pressure lowering. Caution is advised when tadalafil is used as a treatment for ED in men taking alpha-blockers. (2.7, 5.6, 7.1, 12.2) Patients should seek emergency treatment if an erection lasts >4 hours. Use tadalafil with caution in patients predisposed to priapism (5.3).

Source: FDA prescribing information (DailyMed). Set ID: 81222924-29d9-4031-954d-132923867b8e. SPL document ID: d1b827f1-2de5-4a6c-a8eb-534ef1b39f2b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tadalafil (BPH) (FDA label)

Tadalafil can potentiate the hypotensive effects of nitrates, alpha-blockers, antihypertensives or alcohol (7.1). CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase tadalafil exposure (2.7, 5.10, 7.2) requiring dose adjustment: Tadalafil for use as needed: no more than 10 mg every 72 hours Tadalafil for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease tadalafil exposure (7.2). 7.1 Potential for Pharmacodynamic Interactions with Tadalafil Nitrates - Administration of tadalafil to patients who are using any form of organic nitrate, is contraindicated. In clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates. In a patient who has taken tadalafil, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of tadalafil before nitrate administration is considered.

Source: FDA prescribing information (DailyMed). Set ID: 81222924-29d9-4031-954d-132923867b8e. SPL document ID: d1b827f1-2de5-4a6c-a8eb-534ef1b39f2b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.